Stock analysts expect Immuneering Co. (NASDAQ:IMRX – Get Rating) to post earnings of ($0.51) per share for the current fiscal quarter, reports Zacks Investment Research. Four analysts provided Immuneering earnings estimates, with the highest EPS estimate of $0.46 and the lowest estimate of $0.54. Immuneering posted earnings per share of ($1.61) in the same quarter last year, which would indicate a positive growth rate of 68.3% year over year. The company is due to announce its next quarterly earnings report on Monday, January 1.
On average, analysts expect Immuneering to report annual earnings of ($2.10) per share for the current fiscal year, with EPS estimates ranging from ($2.25) to ($1. $83). For the next fiscal year, analysts expect the company to post earnings of ($2.43) per share, with EPS estimates ranging from ($2.83) to ($2.02). Zacks Investment Research’s EPS calculations are an average average based on a survey of analysts who follow Immuneering.
Immuneering (NASDAQ:IMRX – Get Rating) last announced its results on Thursday, March 10. The company reported ($0.42) earnings per share for the quarter, missing analyst consensus estimates of ($0.39) by ($0.03). Immuneering had a negative return on equity of 38.00% and a negative net margin of 2,651.85%. The company posted revenue of $0.19 million in the quarter, versus a consensus estimate of $0.60 million.
IMRX has been the subject of a number of recent analyst reports. Oppenheimer assumed coverage for Immuneering’s stock in a Thursday, March 31, report. They set an “outperform” rating and a price target of $25.00 for the stock. Zacks Investment Research downgraded Immuneering from a “buy” rating to a “hold” rating in a Friday, May 13 research note. Two equity research analysts gave the stock a hold rating and five gave the company a buy rating. According to data from MarketBeat.com, Immuneering has an average rating of “Buy” and an average target price of $29.13.
NASDAQ:IMRX shares opened at $4.48 on Wednesday. The company has a market capitalization of $118.23 million and a PE ratio of -1.50. The stock’s 50-day moving average is $5.78 and its 200-day moving average is $11.36. Immuneering has a 1-year minimum of $3.74 and a 1-year maximum of $33.99.
Separately, director Laurie Keating purchased 7,000 shares of the company in a transaction that took place on Monday, May 16. The shares were purchased at an average price of $5.00 per share, with a total value of $35,000.00. Following the purchase, the director now owns 14,000 shares of the company, valued at $70,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, director Ann E. Berman purchased 6,000 shares of the company in a trade on Tuesday, March 15. The shares were acquired at an average cost of $6.40 per share, with a total value of $38,400.00. Disclosure of this purchase can be found here. In the past 90 days, insiders have purchased 21,451 shares of the company worth $123,501.
A number of large investors have recently increased or reduced their holdings in IMRX. UBS Group AG acquired a new position in Immuneering during Q3 worth approximately $30,000. Citigroup Inc. acquired a new position in Immuneering stock during Q3 worth $33,000. California State Teachers Retirement System increased its holdings of Immuneering shares 81.8% in the first quarter. California State Teachers Retirement System now owns 8,124 shares of the company valued at $53,000 after buying 3,656 additional shares in the last quarter. American International Group Inc. increased its stake in Immuneering by 111.1% in the 1st quarter. American International Group Inc. now owns 9,432 shares of the company valued at $61,000 after purchasing an additional 4,964 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new position in Immuneering in Q3 worth approximately $75,000. Hedge funds and other institutional investors hold 47.41% of the company’s shares.
About Immunization (Get an assessment)
Immuneering Corporation, a biopharmaceutical company, is focused on product candidates in oncology and neuroscience. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat cancer patients, including pancreatic cancer, melanoma, colorectal cancer and non-small cell lung cancer caused by mutations RAS and/or RAF; and IMM-6-415 to treat solid tumors.
Get a Free Copy of Zacks Immunization Research Report (IMRX)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Immuneering Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Immuneering and related companies with MarketBeat.com’s free daily email newsletter.